NovoCure Ltd — Director's Dealing 2020

Mar 6, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2020-03-03

Reporting Person: GROENHUYSEN WILHELMUS CM (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-03	Restricted Share Units	A	24025	—	Acquired	143509	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-03	Options to Buy Ordinary Shares	$69.37	A	46323	Acquired	2030-03-02	Ordinary Shares (46323.0)	Direct

Footnotes

F1: Represents restricted share units that are scheduled to vest on March 3, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.

F2: Options to buy 46,323 ordinary shares will vest and become exercisable in equal installments on each of March 3, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.